Neuberger Berman Group
KYMR icon

Neuberger Berman Group’s Kymera Therapeutics KYMR Stock Holding History

Neuberger Berman Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Sell
3,038
-68,078
-96% -$5.85M ﹤0.01% 1939
2026
Q1 		$5.92M Buy
71,116
+12,634
+22% +$1M ﹤0.01% 944
2025
Q4 		$4.55M Buy
+58,482
New +$3.95M ﹤0.01% 990
2024
Q4 		– Sell
-78,236
Closed -$3.7M – 1977
2024
Q3 		$3.7M Sell
78,236
-40,956
-34% -$1.81M ﹤0.01% 1004
2024
Q2 		$3.56M Sell
119,192
-5,987
-5% -$207K ﹤0.01% 982
2024
Q1 		$5.03M Sell
125,179
-116,979
-48% -$4.19M ﹤0.01% 922
2023
Q4 		$6.17M Buy
+242,158
New +$4.33M ﹤0.01% 1019

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Neuberger Berman Group's KYMR Position: Q2 2026 in Review

Neuberger Berman Group reduced its Kymera Therapeutics (KYMR) stake by 96% in Q2 2026, selling an estimated $5.85M and leaving 3,038 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #1939.

Neuberger Berman Group first reported a position in KYMR in Q4 2023 and has held it in 7 quarters since. The position peaked at $6.17M in Q4 2023. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Neuberger Berman Group held 3,038 shares of Kymera Therapeutics worth $348K as of Q2 2026.
  • Neuberger Berman Group sold 68,078 Kymera Therapeutics shares in Q2 2026, an estimated $5.85M.
  • Kymera Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1939 holding.
  • Neuberger Berman Group first reported a position in Kymera Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • Neuberger Berman Group's Kymera Therapeutics position peaked at $6.17M in Q4 2023.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.